分子靶向治疗是肺癌治疗的新方法。
Molecular targeted therapies are new approaches in lung cancer treatment.
近年来分子靶向治疗逐渐成为研究热点。
In recent years, molecular targeted therapy has become a hot spot.
分子靶向治疗将为食管癌提供更多、更好的选择。
Molecule targeted therapy as a promising treatment will provide more and better options for patients.
本文针对肝癌的分子靶向治疗的研究进展做一综述。
This review attempts to concisely summarize the molecularly targeted therapy of advanced hepatocellular carcinoma.
本文就胰腺癌分子靶向治疗研究的进展做一简要综述。
This article reviews progress in the research of molecule-targeted therapy.
本文主要对肺癌的分子靶向治疗研究进展进行概括总结。
This article will summarize the new development of molecular targeted therapies currently in lung cancer.
甚至有人提出OPN可以作为肿瘤分子靶向治疗的一个靶点。
Even someone posed that OPN can be regarded as a target for molecular targeted therapy of many kinds of tumors.
目的端粒酶在多种肿瘤细胞中高表达，可能是肿瘤分子靶向治疗的一个理想靶点。
Aim Telomerase is highly expression in most tumor cells, and it is an ideal target for cancer molecular targeting therapy.
对晚期不能手术的患者采用先化疗后分子靶向治疗的续贯疗法可取得较好的疗效。
For patients who are inoperable and in the advanced stage, chemotherapy combined with molecular targeted therapy can have better therapeutic effect.
应用伊马替尼对包含该突变体的肿瘤进行分子靶向治疗，多数患者表现为药物抵抗。
The most GISTs are drug-resistant when be treated with imatinib which is a molecular targeted drug.
分子靶向治疗比传统的化疗特异性强、毒副反应小，将成为今后肿瘤治疗的新趋势。
Molecular targeted therapy has limited or nonexistent side effects on normal cells of the body, unlike traditional chemotherapy.
微创治疗联合生物治疗和分子靶向治疗的新模式将成为新世纪肿瘤治疗的重要组成部分。
The new mode of combined minimally invasive therapy with bio-immunotherapy is expected to be the most important part of cancer treatment in the 21st Century.
然而，在临床中，仍有近三成的病人使用了目前国际上最先进的分子靶向治疗药物却没有效果。
However, in clinical practice, there are still Jinsan Cheng patients to use the current world's most advanced molecular targeted therapies have no effect.
而对于食管癌的分子靶向治疗，目前尚处于萌芽阶段，也是食管癌治疗研究的重点，并具有广阔的前景。
The molecular targeted therapy for esophageal cancer, still in its infancy, is also an important area of the study in future esophageal cancer treatment.
分子靶向治疗是近年来肿瘤治疗的一个闪光点，凭着它的特异性和有效性，目前已成为国内外肿瘤治疗的研究热点。
Molecularly targeted therapy is a highlight of new pattern for cancer treatment, which has been a Research hot spot in recent years with its Specificity and Efficacy.
由于GIST分子靶向治疗的成功，GIST越来越受到人们的关注，因此，有必要对GIST的临床病理研究作一概述。
Along with the success of targeted therapy of GIST, the disease was paid more attention. Therefore, a review of the clinical pathological study...
肺癌分子靶向治疗近年来取得较大进展，特别是针对表皮生长因子受体(EGFR)分子靶向药物表现出确定的临床效果。
Molecular targeted therapy has a advance development, the molecular targeted therapies drug for epidermal growth factor receptor (EGFR) present definite clinic effect.
KRAS基因突变在恶性肿瘤组织中频发，可预测非小细胞肺癌分子靶向治疗的疗效和预后，针对RAS基因的分子抑制剂研究仍处于初级阶段。
KRAS mutation frequency in tumor tissue, can be predicted non-small cell lung cancer molecular targeted therapy efficacy and prognosis, and molecular inhibitors of RAS genes is still in its infancy.
Lapatinib是一种分子药物市场蓬勃发展的产品——被设计用来靶向治疗与疾病相关的特定的蛋白质分子。
Lapatinib is a product of the growing field of molecular medicine-the design of drugs to attack specific protein molecules associated with particular diseases.
首先，研究人员不知道人类成血干细胞同样的分子是否刚好是治疗的靶向细胞。
First, the researchers don't know whether the same molecule on human blood-forming stem cells would be the right one to target with a therapy.
虽然IPA - 3本身可能不适合人类使用的药物，但这种分子可以形成一个新的靶向治疗的理论基础。
While IPA-3 itself might not be a suitable as a drug for use in humans, the molecule could form the conceptual basis of a new targeted therapeutic.
最近，新的靶向分子得到了确认，针对肝癌治疗的多种靶向因子正处于研究中。
Recently, new molecular targets have been confirmed and various targeted agents are now being investigated for the treatment of HCC.
这方面的进展代表着在这个复杂疾病处理上的一个突破。肝癌具有多药耐药性，但研究证明这种分子靶向对其治疗是有效的。
This advancement represents a breakthrough in the management of this complex disease, and proves that molecular targeted therapies can be effective in this otherwise chemo-resistant tumor.
深入研究肿瘤血管异质性分子对于肿瘤诊断、血管靶向治疗等具有重要意义。
And it is significant for the diagnosis of tumors and the therapy targeting tumor vasculatures to research the heterogeneous molecules further.
目的：鉴定抑制肺癌细胞生长的功能性单克隆抗体1E2及其抗原，为治疗肺癌提供有潜力的靶向抗体治疗剂和分子靶位。
Objective: To identify a functional monoclonal antibody 1E2 against lung cancer and its antigen, so as to provide a candidate antibody drug and molecule target for the anti-lung cancer therapy.
这些多肽序列在肿瘤血管靶向治疗，肿瘤血管特异性分子标志物试剂的研制方面将具有巨大的潜在价值。
These polypeptide sequences have great potential in the targeting treatment of tumor veins and the development of the symbol reagent of the specific molecule of the tumor veins.
研究显示，PDCD4基因在肿瘤治疗中作为一种分子治疗靶向的可能性。
These studies indicated a potential value of PDCD4 as a molecular target in cancer therapy.
这种靶向性的策略包括目的基因对肿瘤细胞的靶向转移，目的基因在肿瘤细胞中的特异表达，以及基因修饰细胞分泌的肿瘤靶向治疗分子。
This can be achieved by tumor targeted gene transfer or tumor specific gene expression, as well as secretion of tumor targeted therapeutic molecules by autologous normal cells.
英国利兹大学的一项研究已经发现，通过靶向一个分子帮助细胞恢复他们的DNA，可能为一些侵袭性脑肿瘤带来新的治疗方式。
Targeting a molecule that helps cells repair their DNA could lead to a new treatment for some aggressive brain tumours, a University of Leeds study has found.
英国利兹大学的一项研究已经发现，通过靶向一个分子帮助细胞恢复他们的DNA，可能为一些侵袭性脑肿瘤带来新的治疗方式。
Targeting a molecule that helps cells repair their DNA could lead to a new treatment for some aggressive brain tumours, a University of Leeds study has found.
应用推荐